# BRUIN CLL-322 (NCT04965493)

> A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

No report yet. It can be ordered.

- Drugs tested: pirtobrutinib
- Indication: previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04965493
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Loxo Oncology, Inc.
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Pirtobrutinib; Venetoclax; Rituximab
- Enrollment: 600
- Primary outcome: To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)

## Indexed commentary on BRUIN CLL-322 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bruin-cll-322-nct04965493
